IMV · IMV Inc.
Acquired Company
BioVaxys completed the acquisition of all intellectual property, immunotherapeutics platform technology, and clinical stage assets from IMV Inc. on February 21, 2024.
Pharmaceutical Preparation Manufacturing
Manufacturing
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
N/A
Open
N/A
Volume
N/A
Day Range
N/A - N/A
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
0.41%
Institutional Own.
20.37%
Qtr Updated
Mar 31st 2024